Cardiology – Page 18

Pregnancy as a Window to Longevity: Maternal Biomarkers at 29 Weeks Predict Long-Term Cardiovascular Risk

By MedXY 02/20/2026

A Danish cohort study demonstrates that specific pregnancy biomarkers, particularly sFlt-1 and hs-cTnI measured at 29 weeks, significantly enhance the prediction of long-term cardiovascular disease risk in women, independent of traditional clinical factors and hypertensive disorders of pregnancy.

Cardiology news Oncology

GnRH Agonists Linked to Accelerated Coronary Plaque Progression Compared to Antagonists in Prostate Cancer Patients

By MedXY 02/19/2026

A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offering a potential biological explanation for differential cardiovascular risks.

Cardiology Internal Medicine news

Challenging the Label: Large-Scale Meta-Analysis Refutes Most Statin-Attributed Adverse Effects

By MedXY 02/16/2026

A comprehensive meta-analysis of double-blind RCTs by the CTT Collaboration reveals that the majority of adverse effects listed on statin labels, including cognitive and sleep issues, lack causal evidence, suggesting a need for urgent regulatory revisions.

Cardiology news Pediatrics

Early Life Origins of Hypertension: Longitudinal Evidence That Blood Pressure Tracks from Birth to School Age

By MedXY 02/10/2026

A longitudinal study of the ENVIRONAGE cohort reveals that blood pressure tracks consistently from birth through childhood, with higher neonatal readings significantly increasing the risk of hypertension by age 11, emphasizing the need for early life cardiovascular monitoring.

Cardiology news Oncology

Environmental Cardiotoxicity: PM2.5 and Ozone Exposure Double the Risk of Cardiac Dysfunction in Breast Cancer Patients

By MedXY 02/09/2026

A prospective study reveals that PM2.5 and ozone exposure significantly exacerbate cardiac dysfunction and adverse remodeling in breast cancer patients receiving anthracyclines or trastuzumab, doubling the risk of clinical LVEF decline.

Cardiology General Surgery news

Rapid Ultraoxygenated Recovery Eliminates the Need for Preimplant Reanimation in DCD Heart Transplants

By MedXY 02/09/2026

A JAMA study demonstrates that Rapid Ultraoxygenated Recovery (REUP) enables successful DCD heart transplantation without preimplant reanimation, achieving 96% survival despite extended ischemic times and older donors, potentially offering a more efficient, ethical alternative to current procurement strategies.

Cardiology Internal Medicine news

Caffeinated Coffee Linked to 39% Lower Risk of Atrial Fibrillation Recurrence: Results from the DECAF Randomized Trial

By MedXY 02/09/2026

The DECAF randomized trial challenges the traditional view of caffeine as a trigger for atrial fibrillation, demonstrating that coffee consumption significantly reduces arrhythmia recurrence after cardioversion compared to total abstinence.

Cardiology Emergency Medicine news

Minutes Matter: How Modern Medicine is Winning the Race Against Heart Attacks

By MedXY 02/08/2026

An extensive study of 575,247 patients reveals significant improvements in hospital response times for heart attacks over the last decade, yet highlights critical gaps in care for women, elderly patients, and those admitted during off-hours.

Cardiology Infectious Diseases news

RSV-Related Hospitalization Linked to Surge in Acute Myocardial Infarction and Stroke Risk

By MedXY 02/06/2026

A large-scale study reveals that RSV hospitalization significantly increases the risk of myocardial infarction, stroke, and heart failure exacerbations, with the highest risk occurring within the first week post-admission, emphasizing the critical need for adult vaccination.

Cardiology news Pediatrics

Over 50% of Publicly Insured Children Face Neurodevelopmental Disorders Following Infant Heart Surgery

By MedXY 02/05/2026

A comprehensive study highlights that over half of publicly insured children develop neurodevelopmental disorders within five years of infant cardiac surgery. While service utilization is high, a critical gap persists between initial screening and specialized evaluations required for optimal outcomes.

Cardiology General Surgery news

Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring

By MedXY 02/05/2026

The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical blood loss, suggesting other factors drive perioperative bleeding.

Cardiology news Public Health

Semaglutide for Secondary CVD Prevention: Evaluating the Price of Clinical Success

By MedXY 02/05/2026

A simulation study reveals that while semaglutide significantly reduces cardiovascular events in adults with obesity, its current cost exceeds traditional cost-effectiveness thresholds, requiring an 18% price reduction for broader economic viability.

Cardiology Hematology-Oncology news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

By MedXY 02/05/2026

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer alternative for high-risk geriatric populations.

Cardiology General Surgery news

Anatomically Directed HGF Gene Therapy Significantly Accelerates Ulcer Healing in Chronic Limb-Threatening Ischemia: Insights from the LEGenD-1 Trial

By MedXY 02/04/2026

The LEGenD-1 trial demonstrates that intramuscular HGF gene therapy (AMG0001) significantly reduces healing time for neuroischemic ulcers in patients with moderate chronic limb-threatening ischemia, offering a potential nonsurgical therapeutic breakthrough for an underserved patient population.

Cardiology Internal Medicine news

Beyond HDL-C: How Macronutrient Shifts Reshape HDL Subspecies to Reduce Coronary Risk

By MedXY 02/04/2026

The OmniHeart trial reveals that replacing dietary carbohydrates with unsaturated fats or protein favorably modifies 15 minor protein-based HDL subspecies, shifting the proteomic profile toward lower coronary heart disease risk, independent of total HDL-C levels.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream strategy for rhythm control.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable CAD: The FAME 2 Trial

By MedXY 02/04/2026

The 11-year FAME 2 trial results confirm that FFR-guided PCI significantly improves outcomes for stable CAD patients with functionally significant lesions, primarily by reducing urgent revascularizations, reinforcing the importance of physiological assessment in revascularization decisions.

Cardiology Diabetes & Endocrinology news

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

By MedXY 02/04/2026

This real-world study demonstrates that GLP-1 receptor agonists significantly reduce AF recurrence, progression to permanent AF, and cardiovascular hospitalizations in obese patients following catheter ablation, highlighting their role as a critical adjunctive therapy in metabolic-arrhythmic management.

Cardiology news

Bridging the Gap: Why In-Procedure QFR Variability May Explain the FAVOR III Europe Outcomes

By MedXY 02/04/2026

The REPEAT-QFR study reveals modest agreement between in-procedure and core laboratory quantitative flow ratio (QFR) measurements, suggesting that angiographic quality and user adherence significantly impact diagnostic accuracy.

Cardiology news

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY 02/04/2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable win ratio of 1.25.